Cervical cancer incidence higher in states with lower proportion of HPV vaccination rates
the ONA take:
According to new findings presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved in San Antonio, Texas, researchers from the University of North Carolina Gillings School of Global Public Health in Chapel Hill, North Carolina, the number of adolescent girls receiving the human papillomavirus (HPV) vaccine is much lower in states with higher rates of cervical cancer and cervical cancer-related mortality.
Using the National Immunization Survey-Teen, researchers identified the rates of HPV vaccination in various states, and identified cervical cancer rates in the same states using the United States Cancer Statistics database. States with higher vaccination rates had lower cancer incidence rates and vice versa.
For example, in Massachusetts, 69% of adolescent girls have begun the HPV vaccination series and 6 per 100,000 women develop cervical cancer a year, whereas in Arkansas, 41% of adolescent girls have initiated HPV vaccination and 10 per 100,000 women develop cervical cancer a year. In addition, completion rates of the HPV vaccine course were higher in states where adolescents have higher levels of contact with the healthcare system.
The researchers suggest that more adolescent preventive health care may be needed to improve completion rates of the HPV vaccination series.
Number of adolescent girls receiving the HPV vaccine much lower in states with higher rates of cervical cancer.
The proportion of adolescent girls receiving human papillomavirus (HPV) vaccines was much lower in states with higher rates of cervical cancer incidence and mortality, according to data presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Nov. 9–12.
HPV vaccines can prevent individuals from developing several types of cancer, including cervical, anal, vaginal, and vulvar cancers. "Cervical cancer incidence and mortality rates vary widely by state," said Jennifer L. Moss, MSPH, a doctoral student in the Department of Health Behavior at the University of North Carolina Gillings School of Global Public Health in Chapel Hill.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|